Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07010302 · ClinicalTrials.gov registry record · Phase 4
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Phase 4
- Development phase
- 540
- Enrollment target
NCT07010302: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT07010302 is a Phase 4 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 540 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07010302, a Phase 4 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 540 participants
- Enrollment target
Study Summary
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that mainly affects the eyes and spinal cord, causing serious symptoms such as vision loss, paralysis, and severe pain. This trial compares the effectiveness and safety of five medications commonly used to prevent NMOSD relapses: rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab. In this study, 160 adults with NMOSD who test positive for a specific antibody (AQP4-IgG) will participate. They will be randomly assigned to receive either rituximab or one of the four other FDA-approved medications. The main goal is to find out which treatment best prevents relapses and has fewer serious side effects. The trial will also measure disability, patient satisfaction, quality of life, and biomarkers that help track disease activity. Participants will have regular assessments, including medical exams, surveys, and tests for vision, walking ability, and brain function. They will report any side effects or health issues experienced during the study. The trial will last from one to four years for each participant. This research aims to help patients and doctors make better-informed treatment decisions by providing clear evidence about the best available therapies for NMOSD.
Interventions
- DRUG Satralizumab
- DRUG Inebilizumab
- DRUG Ravulizumab
- DRUG Rituximab (R)
- DRUG Eculizumab (Soliris®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07010302
The ClinicalTrials.gov registry entry for NCT07010302 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Satralizumab is the first listed.
NCT07010302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07010302 about?
NCT07010302 is a clinical study titled "Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD". Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that mainly affects the eyes and spinal cord, causing serious symptoms such as vision loss, paralysis, and severe pain. This trial compares the effectiveness and safety of five medications commonly used to prevent NMOSD re...
What is the current status of trial NCT07010302?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 540 participants. The study started on 2026-08-01. Estimated completion is 2030-05.
What interventions are being tested in trial NCT07010302?
The interventions under investigation include: Satralizumab (DRUG), Inebilizumab (DRUG), Ravulizumab (DRUG), Rituximab (R) (DRUG), Eculizumab (Soliris®) (DRUG).
Who is sponsoring clinical trial NCT07010302?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.